Comparative Study Between (SGLT-2i) and (DPP-4i) in the Prevention of DIC
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Dapagliflozin (5-10 mg daily) - SGLT2 Inhibitor Therapy, Sitagliptin (DPP4 inhibitor), Standard Care (in control arm).
- Who it may be relevant to
- Registry conditions: Breast Cancer. Basic parameters: No limits · Female.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Comparative Clinical Study Evaluating the Efficacy of (SGLT2)Inhibitors Versus (DPP-4) Inhibitors in the Prevention of Doxorubicin-Induced Cardiotoxicity Among Egyptian Women With Breast Cancer
Overview
Background: Breast cancer is the most frequently diagnosed malignancy among women worldwide and a major cause of morbidity and mortality. Anthracycline-based chemotherapy, particularly doxorubicin, remains a cornerstone of treatment; however, its clinical utility is limited by dose-dependent cardiotoxicity that can lead to irreversible cardiac dysfunction and heart failure. The search for effective cardioprotective interventions is therefore a key priority in cardio-oncology. Aim: This study aims to compare the efficacy of sodium-glucose cotransporter 2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors in preventing doxorubicin-induced cardiotoxicity in Egyptian women with breast cancer. Methods: A prospective, randomized, controlled clinical trial will be conducted at Oncology Hospital of Tanta University. Eligible adult female patients with histologically confirmed breast cancer scheduled to receive anthracycline-containing chemotherapy will be randomized into three groups: (1) control (standard care), (2) SGLT2 inhibitor group (dapagliflozin 10-25 mg daily), and (3) DPP-4 inhibitor group (sitagliptin 50-100 mg daily). Treatment will start five days before the first chemotherapy cycle and continue for six months, with follow-up for an additional six months. Cardiac function will be assessed by echocardiography (LVEF and GLS) and biomarkers (Cardiac Troponin T, and NT-proBNP). The primary endpoint is the incidence of cardiotoxicity defined by a ≥10% decline in LVEF to \<50% or a \>15% relative decline in GLS accompanied by biomarker elevation. Expected Outcomes: It is anticipated that both SGLT2 and DPP-4 inhibitors will reduce the incidence and severity of doxorubicin-induced cardiotoxicity, with SGLT2 inhibitors expected to demonstrate superior cardioprotective efficacy. Findings from this study may support the integration of cardioprotective antidiabetic agents into oncology care pathways to improve the cardiac outcomes and overall survival of breast cancer patients.
Interventions
- Drug Dapagliflozin (5-10 mg daily) - SGLT2 Inhibitor Therapy
Dapagliflozin 10 mg orally once daily (dose may increase to 25 mg if tolerated after Cycle 1) starting ≥5 days before first DOX dose and continued for 3 months. - Drug Sitagliptin (DPP4 inhibitor)
Sitagliptin 100 mg orally once daily (50 mg if eGFR 30-45 mL/min/1.73m²) starting ≥5 days before first DOX dose and continued for 3 months. - Other Standard Care (in control arm)
Usual care without prophylactic cardioprotective agent (guideline directed initiation permitted if clinically indicated post randomization; recorded and adjusted for).
Primary outcome measures
- Percentage of participants experiencing cardiotoxicity [Time frame: Within 3 months from initiation of therapy.]
Secondary outcome measures (6)
- Percentage Change in Left Ventricular Ejection Fraction (LVEF) [Time frame: 3 months]
- Percentage Change in Global Longitudinal Strain (GLS) [Time frame: 6 months]
- Time to cardiotoxicity and HF hospitalization through 6 months. [Time frame: 6 months]
- Change in serum cardiac biomarker levels e.g., troponin [Time frame: 3 months]
- Change in serum cardiac biomarker levels (e.g., NT-proBNP) [Time frame: 3 months]
- All cause mortality and cancer therapy interruptions due to cardiac reasons. [Time frame: 6 months]
Eligibility criteria
Inclusion criteria
- Female, ≥18 years, Egyptian nationality.
- Breast cancer (any stage) with planned anthracycline containing chemotherapy (intended cumulative DOX ≥240 mg/m² or epirubicin ≥360 mg/m² equivalents).
- Baseline echo suitable for LVEF ≥53%.
- Able to consent and comply with follow up.
Exclusion criteria
- • Type 1 and type 2 diabetes; history of diabetic ketoacidosis; pregnancy/lactation.
- Symptomatic HF, cardiomyopathy, significant valvular disease, prior anthracycline exposure.
- Baseline hypotension (SBP <95 mmHg), recurrent UTIs/mycotic infections, active foot ulcer/critical limb ischemia.
- Inflammatory diseases, liver and kidney diseases.
- Autoimmune diseases.
- Other type of malignancies or metastatic diseases.
- Patients who exposed to surgery less than one month.
- Concomitant dexrazoxane planned upfront (allowed only for rescue; documented).
- Known hypersensitivity to study drugs.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Prevention
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07436663 · 2467Q8